LimaCorporate
20 Apr_2021

LimaCorporate is proud to announce the first surgery performed in the Stemless Reverse Shoulder System Investigational Device Exemption (IDE) study.

LimaCorporate is proud to announce the first surgery performed in the Stemless Reverse Shoulder System Investigational Device Exemption (IDE) study.
The IDE, approved by FDA last November, allows LimaCorporate evaluate the safety and effectiveness of our Stemless Reverse Shoulder System compared to our Reverse Shoulder System in a randomized, multi-center comparative clinical trial.

This study is an exceptional opportunity for LimaCorporate as there are currently no stemless reverse implants cleared for use by the FDA. LimaCorporate’s IDE study on the Stemless Reverse System, which aims to enroll 200 patients at eight U.S. investigational sites with two-year follow-up, is a pivotal first step to address this unmet need in the U.S. shoulder arthroplasty market.
The IDE Study makes us even more confident about the future: new products, new projects, and activities are growing and taking shape.

Read the full press release here

Other News

20 Mar_2024

PISC 2024: A Week of Innovation and Connection

15 Mar_2024

Introducing the PRIMA Short Stem: a revolutionary addition to our shoulder…

02 Feb_2024

LimaCorporate receives Gender Equality Certification!

18 Jan_2024

New Surgeon/Patient interview with surgeon Dr. D'Amelio and Mr. Zambelli

12 Jan_2024

What did we achieve in 2023 in terms of visibility of LimaCorporate products?

09 Jan_2024

Happy 20th Anniversary Uni-Knee!